Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $550.0 million
Deal Type : Collaboration
Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock RNA Therapies
Details : Under the terms of the agreement, Novo Nordisk and Replicate will collaborate on certain targets for obesity, type 2 diabetes and other cardiometabolic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $550.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration
Novo Nordisk Inks $812M Deep Apple Deal to Pursue Obesity Target
Details : The collaboration aims to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs
Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $870.0 million
Deal Type : Collaboration
Camurus and Lilly Enter Collaborates for Long-Acting FluidCrystal Incretins
Details : Through the collaboration with Lilly, Camurus will leverage FluidCrystal technology in rapidly expanding indication areas obesity, diabetes and other serious chronic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $290.0 million
June 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $870.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $65.0 million
Deal Type : Series B Financing
Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements
Details : The financing will be used for Ampersand's AND™ Platform to identify programmed biologics for the treatment of obesity-related targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $65.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Agreement
Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity
Details : ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Collaboration
Flagship Pioneering Signs Two Agreements Under Pfizer Strategic Partnership
Details : Under the collaboration, Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : RenaissThera
Deal Size : Undisclosed
Deal Type : Collaboration
VedTechBio® Launches RxAgentAI™ And Collaborates with RenaissThera®
Details : RenaissThera will use dedicated research teams from VedTechBio and RxAgentAI to design, test and develop novel small molecular drugs to treat metabolic diseases such as Obesity and Type 2 Diabetes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : RenaissThera
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $530.0 million
Deal Type : Collaboration
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Details : The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $530.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration
Flagship Pioneering and Metaphore Biotechnologies Collaborate with Novo on Obesity
Details : Under the collaboration, Novo will leverage Metaphore's MIMICTM platform in the discovery and development of two multitarget therapeutics leveraging GLP-1R and related biology for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration